Oxford Biomedica strikes new license and supply agreements
13th Dec 2021 07:31
(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.
Read moreBoehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology
19th Oct 2021 09:18
(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.
Read moreOxford Biomedica swings to profit on Covid-19 vaccine sales
22nd Sep 2021 07:03
(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.
Read moreOxford Biomedica swings to profit on Covid-19 vaccine sales
22nd Sep 2021 07:03
(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.
Read moreOxford Biomedica ups revenue forecast as AstraZeneca lifts vaccine output
18th May 2021 08:13
(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Tuesday doubled annual earnings guidance after pharmaceutical giant AstraZeneca ordered more Covid-19 vaccines.
Read moreOxford Biomedica swings to EBITDA profit
15th Apr 2021 09:02
(Sharecast News) - Oxford Biomedica reported a 37% improvement in total revenues in its preliminary results on Thursday, to £87.7m.
Read moreOxford Biomedica strikes three-year deal with Boehringer Ingelheim
6th Apr 2021 08:08
(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors.
Read moreOxford Biomedica says Sanofi pulling out of haemophilia project
19th Mar 2021 07:50
(Sharecast News) - Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.
Read moreOxford Biomedica strikes collaboration agreement with PhoreMost
9th Nov 2020 09:16
(Sharecast News) - Gene and cell therapy group Oxford Biomedica has inked a discovery collaboration agreement with UK-based biopharmaceutical company PhoreMost.
Read moreOxford Biomedica partner delays Parkinson's disease treatment trial
30th Oct 2020 08:47
(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Friday that partner Axovant Gene Therapies had pushed out the start date for its trial into a Parkinson's disease treatment.
Read moreOxford Biomedica new manufacturing suite approved
6th Oct 2020 07:03
(Sharecast News) - Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.
Read moreOxford Biomedica sees swing to FY profit on Covid vaccine hopes
17th Sep 2020 07:01
(Sharecast News) - Drugs maker Oxford Biomedica, which has partnered with pharma giant AstraZeneca to develop a Covid-19 vaccine, said it expected higher second half revenues to push it to a low-to-single digit full year profit.
Read moreOxford Biomedica slumps as AstraZeneca vaccine trial halted
9th Sep 2020 08:31
(Sharecast News) - Oxford Biomedica shares slid on Wednesday on news that AstraZeneca and Oxford University's Covid-19 vaccine trial has been put on hold, as investors fretted over how this might affect the gene and cell therapy company's supply deal with the UK pharmaceuticals giant.
Read moreOxford Biomedica signs deal with Beam Therapeutics
3rd Aug 2020 08:05
(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics, it announced on Monday, which it described as a Massachusetts-based biotechnology company developing precision genetic medicines through the use of base editing.
Read moreOxford Biomedica signs supply deal with Axovant Gene Therapies
31st Jul 2020 08:34
(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a three-year clinical supply agreement with a wholly-owned subsidiary of Axovant Gene Therapies, it announced on Friday.
Read more